111, Inc. (NASDAQ:YI) Short Interest Down 54.5% in March

111, Inc. (NASDAQ:YI - Get Free Report) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 3,000 shares, a drop of 54.5% from the March 15th total of 6,600 shares. Currently, 0.1% of the company's shares are sold short. Based on an average daily trading volume, of 41,200 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On 111

Several institutional investors and hedge funds have recently made changes to their positions in YI. JPMorgan Chase & Co. grew its holdings in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after purchasing an additional 305,339 shares during the period. Napean Trading & Investment Co Singapore PTE Ltd bought a new stake in 111 during the 4th quarter worth approximately $245,000. Finally, FIL Ltd purchased a new position in 111 during the fourth quarter valued at approximately $450,000. Institutional investors own 21.32% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of 111 in a report on Tuesday, April 8th.

111 Stock Performance

Shares of YI traded up $0.19 during mid-day trading on Friday, reaching $7.50. The company had a trading volume of 1,855 shares, compared to its average volume of 23,237. 111 has a 52 week low of $4.15 and a 52 week high of $14.10. The company has a market capitalization of $64.14 million, a price-to-earnings ratio of -1.88 and a beta of 0.57. The firm has a 50-day moving average price of $8.29 and a 200 day moving average price of $7.51.

111 (NASDAQ:YI - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $527.14 million during the quarter.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.